

Effects of tea or tea extract on metabolic profiles in patients with type 2 diabetes mellitus: a meta-analysis of 10 randomized controlled trials

Yanchuan Li^{1, 2, †} · Cheng Wang^{3, 2, †} · Qingjie Huai^{4, †} · Fuchuan Guo^{1, 2} · Liyan Liu^{1, 2} · Rennan Feng^{1, 2, *} · Changhao Sun^{1, 2, *}

¹Department of Nutrition and Food Hygiene, School of Public Health, Harbin Medical University, Harbin, China

²National Key Discipline, School of Public Health, Harbin Medical University, Harbin, China

³Department of Environmental Hygiene, School of Public Health, Harbin Medical University, Harbin, China

⁴Department of Virus, Harbin Center for Disease Control and Prevention, Harbin, China

[†] Authors contributed equally to this work.

^{*}Corresponding authors. Telephone: +86 0451 87502801; fax number: +86 0451 87502885.

E-mail: fengrennan@gmail.com; changhao2002sun@gmail.com

Running title: Effects of tea on T2DM patients.

Electronic word count: abstract 250, main text 2213

Numbers of tables: 6

Numbers of figures: 2

Numbers of references: 44

This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version of Record. Please cite this article as doi: 10.1002/dmrr.2641

Abbreviations

ADPN

CRE

CRP

DBP

EC

ECG

EGC

EGCG

FBG

FBI

SBP

T2DM

UA

Adiponectin

Creatinine

C-reaction protein

Diastolic blood pressure

Epicatechin

Epicatechin-3-gallate

Epigallocatechin

Epigallocatechin gallate

Fasting blood glucose

Fasting serum insulin

Systolic blood pressure

Type 2 diabetes mellitus

Uric acid

ABSTRACT:

Background: As consumption of tea has been confirmed as a protective factor for type 2 diabetes mellitus (T2DM), it would be interesting to know if T2DM patients could benefit from tea. Because of small sample sizes and inconsistent results of previous studies, we performed this meta-analysis to reevaluate the effects of tea or tea extract on all available outcomes in patients with T2DM.

Methods: We systematically searched electronic databases of PubMed, Cochrane Library and EMBASE to identify randomized controlled trials of tea in T2DM patients up to January 2015. Weight mean differences for the changes in all outcomes were pooled by Review manager 5.2.

Results: A total of 10 trials including 608 subjects were identified. The meta-analysis found that tea could alleviate the decrease of fasting blood insulin [1.30 U/L, 95% CI (0.36, 2.24)], and reduced waist circumference only in more than 8 weeks intervention [-2.70 cm, 95% CI (-4.72, -0.69)], whereas there were no statistically significant differences with regard to HOMA-IR 0.38 (-0.18, 0.95), fasting blood glucose -0.05 mmol/L (-0.51, 0.40), LDL-c 0.07 mmol/L (-0.15, 0.29), HDL-c 0.01 mmol/L (-0.08, 0.09), BMI -0.15 kg/m² (-0.50, 0.21), SBP 0.35 mmHg (-3.54, 4.24), DBP -1.02mmHg (-3.53, 1.48), TG -0.11mmol/L (-0.28, 0.05), and TC -0.05mmol/L (-0.20, 0.11) in patients with T2DM, and leptin, ADPN, CRE, and UA were also non-significant.

Conclusions: The intervention of tea or tea extraction could maintain a stable fasting blood insulin and reduce waist circumference in the T2DM patients, however, the effects on other outcomes were not significant.

Keywords: tea; T2DM; metabolic profile; meta-analysis

INTRODUCTION

Over the past decades, there has been a rapidly raise in the prevalence of type 2 diabetes mellitus (T2DM) in the world (1). WHO estimations had predicted that 350 million people worldwide will suffer diabetes by the year 2030 (2). For diabetes is the fifth leading cause of death in the world, entailing related morbidity and mortality, useful preventive strategies for the complication of diabetes are urgently needed (3).

As oxidative stress is regarded as an underlying mechanism in the progress of insulin resistance, impaired blood glucose and lipid metabolism and β -cell dysfunction in T2DM (4-6), many anti-oxidative stress agents were investigated for the protection of diabetic complications. Tea, derived from the plant *Camellia sinensis*, is one of the most widely consumed beverages in the world next to water (7). Depending on the level of fermentation, tea can be classified into three types: green tea (unfermented), oolong tea (partially fermented) and black tea (complete fermented). Green tea contains more catechins, including epigallocatechin gallate (EGCG), epicatechin-3-gallate (ECG), epigallocatechin (EGC), and epicatechin (EC) (8). Black tea and oolong tea contain more theaflavins and thearubigins (9).

Tea could reduce the risk for T2DM, which has been reported many cohort studies and meta-analyses (10-12). Green tea polyphenols have been shown to scavenge free radicals, decrease lipid peroxidation by increasing the activity of superoxide dismutase and glutathione, and also have anti-diabetic effects (13). Recent meta-analyses reported that green tea beverages or extracts could significantly reduce serum TC and LDL-cholesterol concentrations (14), and reduce FBG in the mixed population of RCT studies (15). Based on current beneficial effects of tea in general population, it would be important to determine if favorable effects of tea still exist in patients with T2DM. A number of RCT studies have reported the beneficial effects of tea or its extract (16-22), but not all (23-25).

Therefore, in this study, we included all the RCT studies to combine the data and evaluate more precise effects of tea or its extract on body weight, blood glucose, lipids, insulin, insulin sensitivity and inflammation in T2DM patients.

METHODS

Literature search

Relevant studies were searched from electronic databases, including PubMed, EMBASE, and Cochrane Library up to January 2015. Search terms included 'tea' and 'diabetes', 'diabetes mellitus', 'diabetic', 'T2DM', or 'DM' and 'population' or 'trial'. In addition, the reference in retrieved articles were further hand-scanned to add potential eligible studies.

Study selection

All eligible studies should meet the following criteria: (1) The studies must be RCTs; (2) The patients with T2DM; (3) The intervention was tea or tea extract and placebo or water was applied as comparison of intervention; (4) Articles reported at least one of the outcomes: body weight, body mass index (BMI), waist circumference, systolic blood pressure (SBP), diastolic blood pressure (DBP), fasting blood glucose (FBG), fasting serum insulin (FBI), glycosylated hemoglobin (HbA1c), homeostasis model of insulin resistance (HOMA-IR) index, triglycerides (TG), fasting cholesterol (TC), HDL-cholesterol, LDL-cholesterol, leptin, adiponectin (ADPN), ghrelin, creatinine (CRE), uric acid (UA), and C-reaction protein (CRP). Two authors (Y-C. L. and R-N. F.) did the searching and extraction independently and disagreements were resolved by a third author (C. W.).

Quality and evidence level assessment

The methodological quality of the included studies were evaluated. We determined the risk of bias according to the Cochrane Handbook from the Cochrane collaboration guideline (26). We classified items of sequence generation, concealment of allocation, blinding, incomplete outcome data, selective outcome reporting and other sources of bias as: yes, no or unclear. According to the Grading of Recommendations Assessment Development and Evaluation approach, the quality of evidence for each outcome was graded as high, moderate, low and very low with regard to study limitations, inconsistency of results, indirectness of evidence, imprecision and publication bias (27).

Data extraction

Data extraction was conducted by two authors (Y-C. L. and R-N. F.) independently and in duplicate. All of these items, including the first author's name, year of publication, country and study design, demographic characteristics of the participants, sample sizes of treatment and control groups, dosage of tea or tea extract, duration of treatment and outcomes. The data were compared and the disagreements were resolved by a third author (C.W.).

Statistical analysis

REVMAN 5.2 (Cochrane Collaboration, Oxford, England) was employed for data analysis. The area of the black square in forest plots indicates the weight contributed by each study. Heterogeneity was estimated through the I^2 -test statistic, which estimated the extent of variability across studies. Substantial heterogeneity exists when values I^2 exceeds 50% or $P < 0.05$, the random-effect model were used, otherwise, fixed-effect model was applied. To evaluate the influence of each single study on the combined results, the stability of the results were evaluated through one-leave-out and publication bias were evaluated through funnel plots. P -values were two-tailed and $P < 0.05$ was considered as statistical significance.

RESULTS

Literature search and study selection

Figure 1 presents a flow chart showing the detailed process of study selection. The primary search found a total of 622 relevant articles. After further screening the titles of all achieved articles briefly, 121 articles were identified for further screening and 501 articles that were apparently not relevant to current studies were excluded. Then we screened titles and abstracts of each articles and 16 articles were remained for further full-text evaluation. Of these articles, 5 articles were excluded for the reasons as follows: duplicate study ($n=1$), no target outcomes reported ($n=3$), no controls ($n=1$), not only tea extracts as intervention ($n=1$). Finally, 10 eligible studies were included in our study (16-25).

The characteristics of the studies included

The characteristics of the studies included are presented in Table 1. The 10 articles included involving 608 participants. The duration of intervention ranged from 4 to 16 weeks. Of the 10 included studies, 2 studies reported sequence generation using either computer-generated numbers or a table of random numbers; 4 trials mentioned the details method of blinding.

Methodological quality

Of the 10 included studies, 2 articles reported sequence generation using random numbers (24) or computer generated numbers (20). No articles mentioned allocation concealment. 5 articles described the details of blinding (18, 20, 22, 24, 25). Other information is provided in Table S1.

Changes of treatment group after intervention

We extracted 16 anthropometry or biochemistry indexes, including body weight, BMI, waist circumference, FBG, FBI, HbA1c, HOMA-IR, TG, TC, HDL-cholesterol, LDL-cholesterol, leptin, ADPN, ghrelin, CRE, and UA. The results of all the variables were inconsistent among the studies.

Pooled effects of overall tea or tea extract on variables of body weight, blood lipid, glucose and insulin sensitivity and inflammation

We conducted a systematically meta-analysis on 16 anthropometry and metabolic profile indexes (Table 2, 3 and S2). Results of these analysis showed that tea or tea extract alleviated the decrease of FBI (1.30 [0.36, 2.24], $P = 0.005$; number of studies = 7). For the analysis in more than 8 weeks intervention studies, overall tea or tea extract reduced waist (-2.70 [-4.72, -0.69], $P = 0.009$; number of studies = 5). However, it showed no significant differences of changes in other variables between treatment groups and control groups. Considering of phenolic compounds in green and black tea are markedly different, we analyzed data of green tea or green tea extracts separately (Table 4 and Figure 2). Results showed that green tea or green tea extract alleviated the decrease of FBI (1.51 [0.05, 2.97], $P = 0.04$; number of studies = 6).

Publication Bias

No significant publication biases were detected in the graphed funnel plots of the our meta-analyses, which were provided in Figure S1.

Sensitive Analysis

To determine the influence of each single study on the combined results, we assessed the stability of the results through one-leave-out. After excluding each of the studies, the mean differences between treatment and control groups ranged in a small section, but there were no studies observed to have significant effect on the result of current meta-analysis, which further strengthened our findings before. Data were provided in Table S3.

DISCUSSION

To the best of our knowledge, this meta-analysis firstly comprehensively evaluated the effect of tea or tea extract on metabolic profiles in patients with T2DM from all available RCTs. Tea or tea extract alleviated the decrease of FBI. And in more than 8 weeks intervention studies, overall tea or tea extract reduced waist. However, the pooled data showed non-significant or clinically meaningful effects of tea or tea extracts on body weight, BMI, FBG, HbA1c, HOMA-IR, TG, TC, HDL-c, LDL-c, leptin, ADPN, CRE, and UA.

Effects of tea or tea extract on glycemic control and insulin sensitivity

Many researches have investigated the molecular mechanisms of positive effect of tea or tea extracts on glucose metabolism. EGCG as the most abundant compound of catechin in green tea is known with beneficial effects on human health (28). EGCG could remit the status of insulin resistance by inhibiting the proliferation and differentiation in 3T3-L1 adipocyte cells (29), increasing fatty acids oxidation (30), and expression of GLUT-4 in adipose tissue (31). It also has been reported that the protective function of EGCG for β -cell destruction induced by inflammatory cytokine through inhibition of nuclear factor- κ B activation (32). In our previous study, we also found that EGCG could extend lifespan in healthy rats by protecting liver and kidney damage and alleviating age-associated inflammation and oxidative stress through the

inhibition of NF-kappaB signaling by stimulating the longevity factors FoxO3a and SIRT1(33).

In present meta-analysis, a significant alleviated decrease trend of fasting insulin was observed in the tea or tea extract group, which indicates tea or tea extract may have beneficial effects on secretory ability of pancreatic islets. Insulin secretory ability, insulin content and glucose-stimulated insulin secretion was decreased in patients of T2DM (34). As catechins could protect pancreatic β -cells from inflammation through inhibiting activation of nuclear factor- κ B (32), and based on current meta-analysis, tea or catechins ingestion might protect pancreas islets against damage and maintain insulin secretory ability of pancreatic β -cells in diabetic patients.

The effects of tea on weight loss and weight maintenance

This meta-analysis including 10 articles reported that catechins or an EGCG-cafeine mixture have a mild positive effect on weight reduction and weight maintenance (35). The inhibition in several enzymes may explain the mechanisms tea induced weight loss. Catechins could inhibit the catechol O-methyltransferase and caffeine could inhibit phosphodiesterase; as the degradation of these enzymes, norepinephrine and cAMP rise will be blocked; consequently, parasympathic activity will be increased (36). Moreover, two 24h-intervention studies (36, 37) showed a significant increase in energy expenditure and fatty acid oxidation could be induced by tea or tea extract. However, our study did not found significant effects of tea on body weight in patients with T2DM. However, we speculated that the different of metabolic disorder between healthy subjects and T2DM patients or short period intervention might be the reason.

The effects of tea on serum lipid profile

The effects of green tea and green tea extract on serum lipid profiles has been investigated in both animals and humans by many studies. Hsu et al. have confirmed that green tea could significantly decrease LDL-cholesterol and markedly increase of HDL-cholesterol (38). Other studies showed that green tea consumption could reduce serum cholesterol (39, 40), but not all (41). In our study, we find no significant

influence of tea or tea extract on serum lipid profile of T2DM patients. Thus, further studies on this issue is needed to investigate in T2DM patients.

The effects of tea on blood pressure

The meta-analyses of observational studies had reported the significant inverse relationships between green tea and blood pressure, stroke, coronary artery disease and myocardial infarction (42-44). However, our conclusion failed to find a significant association between green tea and blood pressure in T2DM patients. This conclusion could be compromised by each study designing for diabetic outcomes, but may not fully control potential confounding factors or it is true that tea did not influence the blood pressure in diabetic patients. Therefore, more RCT studies on this issue are needed to clarify in patients with diabetes.

Limitation of current study

Tea is the most widely consumed beverages worldwide, and many people start drinking tea at an early age and continue this habit for a lifetime. The effects of tea on body weight, body fat, insulin sensitivity and glycemic control may be too mild to show significant effects in individuals during a limited period of intervention in diabetic patients. Long period cohort studies may clarify the tea consumption effects on glucose control, insulin sensitivity, body weight management and complications of T2DM. On another hand, the ingredient of tea is complicated, the accurate effects of certain substance should be further investigated. For example, green tea derives from steamed fresh leaves and produced in an unfermented process, which release more catechins, including EGCG, ECG, EGC, and EC. Black and oolong tea contain more theaflavins and thearubigins. Although we could analyze the effects of green tea, we could not further separate the effects of above particular substance.

CONCLUSION

According to current meta-analysis, the intervention of tea or tea extracts might be of benefit for maintain a stable fasting blood insulin and reduce waist circumference. However, it did not show significant effect on other metabolic profiles of T2DM patients. Because of limited duration of intervention, longer duration and high-quality

RCTs are needed to further investigate the effects of different teas on multiple metabolic profiles in patients with T2DM.

Acknowledgements

The study was supported by the National Natural Science Fund of China (81202184), the National 12th Five-Year Scientific and Technical Support Program of China (2012BAI02B02), General Financial Grant from China Postdoctoral Science Foundation (2013M531076) and Research Fund for Innovation Talents of Science and Technology in Harbin City (2013RFQXJ068).

Duality of interest

The authors declare that there is no duality of interest associated with this manuscript.

Contribution statement

Conceived and designed the experiments: R-N. F. and C-H. S. Acquisition, analysis and interpretation of data: Y-C. L., R-N. F. and C. W. Wrote the paper: Q-J. H., Y-C. L. and C-H. S. Revising the manuscript: Q-J. H and F-C. G. and L-Y. L.

REFERENCES

1. King H, Aubert RE, Herman WH. Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections. *Diabetes Care*. 1998;21(9):1414-31.[PubMed:9727886].
2. Guariguata L, Whiting DR, Hambleton I, Beagley J, Linnenkamp U, Shaw JE. Global estimates of diabetes prevalence for 2013 and projections for 2035. *Diabetes research and clinical practice*. 2014;103(2):137-49.[PubMed:24630390].
3. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. *Diabetes Care*. 2004;27(5):1047-53.[PubMed:15111519].
4. Robertson R, Zhou H, Zhang T, Harmon JS. Chronic oxidative stress as a mechanism for glucose toxicity of the beta cell in type 2 diabetes. *Cell biochemistry and biophysics*. 2007;48(2-3):139-46.[PubMed:17709883].
5. Wright E, Jr., Scism-Bacon JL, Glass LC. Oxidative stress in type 2 diabetes: the role of fasting and postprandial glycaemia. *International journal of clinical practice*. 2006;60(3):308-14.[PubMed:16494646].
6. Ceriello A, Motz E. Is oxidative stress the pathogenic mechanism underlying insulin resistance,

diabetes, and cardiovascular disease? The common soil hypothesis revisited. *Arteriosclerosis, thrombosis, and vascular biology*. 2004;24(5):816-23.[PubMed:14976002].

7. McKay DL, Blumberg JB. The role of tea in human health: an update. *Journal of the American College of Nutrition*. 2002;21(1):1-13.[PubMed:11838881].

8. Pastore RL, Fratellone P. Potential health benefits of green tea (*Camellia sinensis*): a narrative review. *Explore*. 2006;2(6):531-9.[PubMed:17113495].

9. Balentine DA, Wiseman SA, Bouwens LC. The chemistry of tea flavonoids. *Critical reviews in food science and nutrition*. 1997;37(8):693-704.[PubMed:9447270].

10. Yang WS, Wang WY, Fan WY, Deng Q, Wang X. Tea consumption and risk of type 2 diabetes: a dose-response meta-analysis of cohort studies. *Br J Nutr*. 2014;111(8):1329-39.[PubMed:24331002].

11. Hayashino Y, Fukuhara S, Okamura T, Tanaka T, Ueshima H, Group H-OR. High oolong tea consumption predicts future risk of diabetes among Japanese male workers: a prospective cohort study. *Diabet Med*. 2011;28(7):805-10.[PubMed:21244473].

12. Oba S, Nagata C, Nakamura K, Fujii K, Kawachi T, Takatsuka N, et al. Consumption of coffee, green tea, oolong tea, black tea, chocolate snacks and the caffeine content in relation to risk of diabetes in Japanese men and women. *Br J Nutr*. 2010;103(3):453-9.[PubMed:19818197].

13. Sabu MC, Smitha K, Kuttan R. Anti-diabetic activity of green tea polyphenols and their role in reducing oxidative stress in experimental diabetes. *Journal of ethnopharmacology*. 2002;83(1-2):109-16.[PubMed:12413715].

14. Zheng XX, Xu YL, Li SH, Liu XX, Hui R, Huang XH. Green tea intake lowers fasting serum total and LDL cholesterol in adults: a meta-analysis of 14 randomized controlled trials. *Am J Clin Nutr*. 2011;94(2):601-10.[PubMed:21715508].

15. Zheng XX, Xu YL, Li SH, Hui R, Wu YJ, Huang XH. Effects of green tea catechins with or without caffeine on glycemic control in adults: a meta-analysis of randomized controlled trials. *Am J Clin Nutr*. 2013;97(4):750-62.[PubMed:23426037].

16. Hosoda K, Wang MF, Liao ML, Chuang CK, Iha M, Clevidence B, et al. Antihyperglycemic effect of oolong tea in type 2 diabetes. *Diabetes care*. 2003;26(6):1714-8.[PubMed:12766099].

17. Fukino Y, Ikeda A, Maruyama K, Aoki N, Okubo T, Iso H. Randomized controlled trial for an effect of green tea-extract powder supplementation on glucose abnormalities. *European journal of clinical nutrition*. 2008;62(8):953-60.[PubMed:17554248].

18. Nagao T, Meguro S, Hase T, Otsuka K, Komikado M, Tokimitsu I, et al. A catechin-rich beverage improves obesity and blood glucose control in patients with type 2 diabetes. *Obesity*. 2009;17(2):310-7.[PubMed:19008868].

19. Neyestani TR, Shariatzade N, Kalayi A, Gharavi A, Khalaji N, Dadkhah M, et al. Regular daily intake of black tea improves oxidative stress biomarkers and decreases serum C-reactive protein levels in type 2 diabetic patients. *Annals of nutrition & metabolism*. 2010;57(1):40-9.[PubMed:20668372].

20. Hsu CH, Liao YL, Lin SC, Tsai TH, Huang CJ, Chou P. Does supplementation with green tea extract improve insulin resistance in obese type 2 diabetics? A randomized, double-blind, and placebo-controlled clinical trial. *Alternative medicine review : a journal of clinical therapeutic*. 2011;16(2):157-63.[PubMed:21649457].

21. Mousavi A, Vafa M, Neyestani T, Khamseh M, Hoseini F. The effects of green tea consumption on metabolic and anthropometric indices in patients with Type 2 diabetes. *Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences*. 2013;18(12):1080-6.[PubMed:24523800].

22. Liu CY, Huang CJ, Huang LH, Chen IJ, Chiu JP, Hsu CH. Effects of green tea extract on insulin resistance and glucagon-like peptide 1 in patients with type 2 diabetes and lipid abnormalities: a randomized, double-blinded, and placebo-controlled trial. *PloS one*. 2014;9(3):e91163.[PubMed:24614112].
23. Ryu OH, Lee J, Lee KW, Kim HY, Seo JA, Kim SG, et al. Effects of green tea consumption on inflammation, insulin resistance and pulse wave velocity in type 2 diabetes patients. *Diabetes research and clinical practice*. 2006;71(3):356-8.[PubMed:16169629].
24. Mackenzie T, Leary L, Brooks WB. The effect of an extract of green and black tea on glucose control in adults with type 2 diabetes mellitus: double-blind randomized study. *Metabolism: clinical and experimental*. 2007;56(10):1340-4.[PubMed:17884442].
25. Mirzaei K, Hossein-Nezhad A, Karimi M, Hosseinzadeh-Attar M, Jafari N, Najmafshar A, et al. Effect of green tea extract on bone turnover markers in type 2 diabetic patients; a double-blind, placebo-controlled clinical trial study. *DARU Journal of Pharmaceutical Sciences*. 2010;17(Suppl 1):38-44.
26. Higgins J, Green S. *Cochrane handbook for systematic reviews of interventions* version 5.1. 0. 2008.
27. Schunemann HJ, Jaeschke R, Cook DJ, Bria WF, El-Solh AA, Ernst A, et al. An official ATS statement: grading the quality of evidence and strength of recommendations in ATS guidelines and recommendations. *American journal of respiratory and critical care medicine*. 2006;174(5):605-14.[PubMed:16931644].
28. Higdon JV, Frei B. Tea catechins and polyphenols: health effects, metabolism, and antioxidant functions. *Critical reviews in food science and nutrition*. 2003;43(1):89-143.[PubMed:12587987].
29. Furuyashiki T, Nagayasu H, Aoki Y, Bessho H, Hashimoto T, Kanazawa K, et al. Tea catechin suppresses adipocyte differentiation accompanied by down-regulation of PPARgamma2 and C/EBPalpha in 3T3-L1 cells. *Bioscience, biotechnology, and biochemistry*. 2004;68(11):2353-9.[PubMed:15564676].
30. Klaus S, Pultz S, Thone-Reineke C, Wolfram S. Epigallocatechin gallate attenuates diet-induced obesity in mice by decreasing energy absorption and increasing fat oxidation. *International journal of obesity*. 2005;29(6):615-23.[PubMed:15738931].
31. Wu LY, Juan CC, Hwang LS, Hsu YP, Ho PH, Ho LT. Green tea supplementation ameliorates insulin resistance and increases glucose transporter IV content in a fructose-fed rat model. *European journal of nutrition*. 2004;43(2):116-24.[PubMed:15083319].
32. Han MK. Epigallocatechin gallate, a constituent of green tea, suppresses cytokine-induced pancreatic beta-cell damage. *Experimental & molecular medicine*. 2003;35(2):136-9.[PubMed:12754418].
33. Niu Y, Na L, Feng R, Gong L, Zhao Y, Li Q, et al. The phytochemical, EGCG, extends lifespan by reducing liver and kidney function damage and improving age-associated inflammation and oxidative stress in healthy rats. *Aging cell*. 2013;12(6):1041-9.[PubMed:23834676].
34. Yang BT, Dayeh TA, Kirkpatrick CL, Taneera J, Kumar R, Groop L, et al. Insulin promoter DNA methylation correlates negatively with insulin gene expression and positively with HbA(1c) levels in human pancreatic islets. *Diabetologia*. 2011;54(2):360-7.[PubMed:21104225].
35. Hursel R, Viechtbauer W, Westerterp-Plantenga MS. The effects of green tea on weight loss and weight maintenance: a meta-analysis. *International journal of obesity*. 2009;33(9):956-61.[PubMed:19597519].

36. Dulloo AG, Duret C, Rohrer D, Girardier L, Mensi N, Fathi M, et al. Efficacy of a green tea extract rich in catechin polyphenols and caffeine in increasing 24-h energy expenditure and fat oxidation in humans. *The American journal of clinical nutrition*. 1999;70(6):1040-5.[PubMed:10584049].
37. Berube-Parent S, Pelletier C, Dore J, Tremblay A. Effects of encapsulated green tea and Guarana extracts containing a mixture of epigallocatechin-3-gallate and caffeine on 24 h energy expenditure and fat oxidation in men. *The British journal of nutrition*. 2005;94(3):432-6.[PubMed:16176615].
38. Hsu CH, Tsai TH, Kao YH, Hwang KC, Tseng TY, Chou P. Effect of green tea extract on obese women: a randomized, double-blind, placebo-controlled clinical trial. *Clinical nutrition*. 2008;27(3):363-70.[PubMed:18468736].
39. Nantz MP, Rowe CA, Bukowski JF, Percival SS. Standardized capsule of *Camellia sinensis* lowers cardiovascular risk factors in a randomized, double-blind, placebo-controlled study. *Nutrition*. 2009;25(2):147-54.[PubMed:18848434].
40. Frank J, George TW, Lodge JK, Rodriguez-Mateos AM, Spencer JP, Minihane AM, et al. Daily consumption of an aqueous green tea extract supplement does not impair liver function or alter cardiovascular disease risk biomarkers in healthy men. *The Journal of nutrition*. 2009;139(1):58-62.[PubMed:19056646].
41. Chan CC, Koo MW, Ng EH, Tang OS, Yeung WS, Ho PC. Effects of Chinese green tea on weight, and hormonal and biochemical profiles in obese patients with polycystic ovary syndrome--a randomized placebo-controlled trial. *Journal of the Society for Gynecologic Investigation*. 2006;13(1):63-8.[PubMed:16378915].
42. Arab L, Liu W, Elashoff D. Green and black tea consumption and risk of stroke: a meta-analysis. *Stroke; a journal of cerebral circulation*. 2009;40(5):1786-92.[PubMed:19228856].
43. Wang ZM, Zhou B, Wang YS, Gong QY, Wang QM, Yan JJ, et al. Black and green tea consumption and the risk of coronary artery disease: a meta-analysis. *The American journal of clinical nutrition*. 2011;93(3):506-15.[PubMed:21248184].
44. Peng X, Zhou R, Wang B, Yu X, Yang X, Liu K, et al. Effect of green tea consumption on blood pressure: a meta-analysis of 13 randomized controlled trials. *Scientific reports*. 2014;4:6251.[PubMed:25176280].

Table 1 Characteristics of 10 randomized controlled trials included in analysis

Trials	Location	Design	Participant	Age	Intervention(dosage)	Comparison	Number (T/C)	Treatment duration
Hosoda (2003)	China	cross-over RCT	T2DM	61.2	oolong tea (1500 ml + 15 g tea leaf)	water	10/10	4 weeks
Ryu (2006)	South Korea	cross-over RCT	T2DM	53.9	green tea (900 ml water + 9 g green tea)	water	55/55	4 weeks
MacKenzie (2007)	America	parallel RCT	T2DM	65	extract of green and black tea (375, or 750 mg per day)	water	17/16/16	3 months
Fukino (2008)	Japan	cross-over RCT	T2DM	32~73	green tea extract powder daily containing 544 mg polyphenols (456 mg catechins)	water	29/31	2 months
Nagao (2008)	Japan	parallel RCT	T2DM	64.9/62.8	catechin (582.8 mg per day)	catechin (96.3 mg per day)	23/20	12 weeks
Mirzaei (2009)	Iran	parallel RCT	T2DM	≥40	GTE capsule (240 mg polyphenols; 150 mg caffeine)	placebo	26/46	8 weeks
Neyestani (2010)	Iran	parallel RCT	T2DM	57.0/55.4	black tea extract (150, 300, 450 and 600 ml per day during week 1, 2, 3, 4)	black tea extract (150 ml per day)	23/23	4 weeks
Hsu (2011)	China	parallel RCT	obese T2DM	20~65	green tea extract (500 mg, three times daily)	placebo (cellulose)	35/33	16 weeks
Mousavi (2013)	Iran	parallel RCT	T2DM	35~65	two or four cups of green tea per day	water	25/24/14	8 weeks
Liu (2014)	China	parallel RCT	T2DM	20~65	green tea extract EGCG (500 mg, three times daily)	placebo (cellulose)	39/38	16 weeks

Table 2 Pooled effects of overall tea or tea extracts on metabolic profiles of T2DM patients and subgroup analyses*

Outcomes	Subgroup	Studies	Participants	Statistical method	Effects estimate	P
weight	All	12	594	Mean Difference (IV, Fixed, 95% CI)	-0.27 [-1.23, 0.70]	NS
	Asia	10	471	Mean Difference (IV, Fixed, 95% CI)	-0.28 [-1.26, 0.70]	NS
	≥8 weeks	9	508	Mean Difference (IV, Fixed, 95% CI)	-0.39 [-1.46, 0.69]	NS
BMI	All	13	665	Mean Difference (IV, Fixed, 95% CI)	-0.15 [-0.50, 0.21]	NS
	Asia	11	543	Mean Difference (IV, Fixed, 95% CI)	-0.16 [-0.52, 0.20]	NS
	≥8 weeks	10	579	Mean Difference (IV, Fixed, 95% CI)	-0.18 [-0.58, 0.22]	NS
waist	All	6	298	Mean Difference (IV, Fixed, 95% CI)	-1.01 [-2.34, 0.32]	NS
	Asia	6	298	Mean Difference (IV, Fixed, 95% CI)	-1.01 [-2.34, 0.32]	NS
	≥8 weeks	5	263	Mean Difference (IV, Fixed, 95% CI)	-2.70 [-4.72, -0.69]	0.009
SBP	All	9	423	Mean Difference (IV, Fixed, 95% CI)	0.35 [-3.54, 4.24]	NS
	Asia	9	423	Mean Difference (IV, Fixed, 95% CI)	0.35 [-3.54, 4.24]	NS
	≥8 weeks	7	383	Mean Difference (IV, Fixed, 95% CI)	0.87 [-3.44, 5.19]	NS
DBP	All	9	423	Mean Difference (IV, Fixed, 95% CI)	-1.02 [-3.53, 1.48]	NS
	Asia	9	423	Mean Difference (IV, Fixed, 95% CI)	-1.02 [-3.53, 1.48]	NS
	≥8 weeks	7	383	Mean Difference (IV, Fixed, 95% CI)	-0.68 [-3.54, 2.18]	NS
TG	All	10	545	Mean Difference (IV, Fixed, 95% CI)	-0.11 [-0.28, 0.05]	NS
	Asia	8	432	Mean Difference (IV, Fixed, 95% CI)	-0.16 [-0.37, 0.06]	NS
	≥8 weeks	9	499	Mean Difference (IV, Fixed, 95% CI)	-0.08 [-0.26, 0.10]	NS
TC	All	10	552	Mean Difference (IV, Fixed, 95% CI)	-0.05 [-0.20, 0.11]	NS
	Asia	8	432	Mean Difference (IV, Fixed, 95% CI)	-0.07 [-0.23, 0.09]	NS
	≥8 weeks	9	506	Mean Difference (IV, Fixed, 95% CI)	-0.08 [-0.29, 0.12]	NS
HDL	All	6	381	Mean Difference (IV, Fixed, 95% CI)	0.01 [-0.08, 0.09]	NS
	Asia	4	263	Mean Difference (IV, Fixed, 95% CI)	-0.00 [-0.10, 0.10]	NS
	≥8 weeks	6	381	Mean Difference (IV, Fixed, 95% CI)	0.01 [-0.08, 0.09]	NS
LDL	All	8	456	Mean Difference (IV, Fixed, 95% CI)	0.07 [-0.15, 0.29]	NS
	Asia	6	340	Mean Difference (IV, Fixed, 95% CI)	0.03 [-0.22, 0.29]	NS
	≥8 weeks	8	456	Mean Difference (IV, Fixed, 95% CI)	0.07 [-0.15, 0.29]	NS

* Subgroup analyses of metabolic profiles of T2DM patients were stratified by: (1) Asia studies; (2) Study duration longer than 8 weeks.

Table 3 Pooled effects of overall tea or tea extracts on glucose control and HOMA-IR of T2DM patients and subgroup analyses*

Outcomes	Subgroup	Studies	Participants	Statistical method	Effects estimate	P
FBG	All	12	658	Mean Difference (IV, Random, 95% CI)	-0.05 [-0.51, 0.40]	NS
	Asia	10	541	Mean Difference (IV, Random, 95% CI)	-0.12 [-0.85, 0.61]	NS
	≥8 weeks	10	572	Mean Difference (IV, Random, 95% CI)	-0.00 [-0.29, 0.28]	NS
FBI	All	7	424	Mean Difference (IV, Fixed, 95% CI)	1.30 [0.36, 2.24]	0.005
	Asia	7	424	Mean Difference (IV, Fixed, 95% CI)	1.30 [0.36, 2.24]	0.005
	≥8 weeks	6	378	Mean Difference (IV, Fixed, 95% CI)	1.51 [0.05, 2.97]	0.04
HbA1c	All	11	602	Mean Difference (IV, Fixed, 95% CI)	-0.07 [-0.19, 0.05]	NS
	Asia	7	424	Mean Difference (IV, Fixed, 95% CI)	-0.26 [-0.57, 0.04]	NS
	≥8 weeks	10	556	Mean Difference (IV, Fixed, 95% CI)	-0.07 [-0.19, 0.05]	NS
HOMA-IR	All	6	419	Mean Difference (IV, Fixed, 95% CI)	0.38 [-0.18, 0.95]	NS
	Asia	6	419	Mean Difference (IV, Fixed, 95% CI)	0.38 [-0.18, 0.95]	NS
	≥8 weeks	4	263	Mean Difference (IV, Fixed, 95% CI)	0.28 [-0.86, 1.41]	NS

* Subgroup analyses of metabolic profiles of T2DM patients were stratified by: (1) Asia studies; (2) Study duration longer than 8 weeks.

Table 4 Pooled effects of green tea or green tea extracts on metabolic profiles of T2DM patients and subgroup analyses

Outcomes	Studies	Participants	Statistical method	Effects estimate	P
weight	7	385	Mean Difference (IV, Fixed, 95% CI)	-0.40 [-1.50, 0.69]	NS
BMI	8	457	Mean Difference (IV, Fixed, 95% CI)	-0.20 [-0.60, 0.21]	NS
waist	5	263	Mean Difference (IV, Random, 95% CI)	-1.64 [-3.84, 0.56]	NS
SBP	7	383	Mean Difference (IV, Fixed, 95% CI)	0.87 [-3.44, 5.19]	NS
DBP	7	383	Mean Difference (IV, Fixed, 95% CI)	-0.68 [-3.54, 2.18]	NS
TG	7	386	Mean Difference (IV, Fixed, 95% CI)	-0.11 [-0.36, 0.14]	NS
TC	7	386	Mean Difference (IV, Fixed, 95% CI)	-0.14 [-0.36, 0.09]	NS
HDL	4	263	Mean Difference (IV, Fixed, 95% CI)	-0.00 [-0.10, 0.10]	NS
LDL	6	340	Mean Difference (IV, Fixed, 95% CI)	0.03 [-0.22, 0.29]	NS
FBG	8	455	Mean Difference (IV, Fixed, 95% CI)	-0.07 [-0.60, 0.47]	NS
FBI	6	378	Mean Difference (IV, Fixed, 95% CI)	1.51 [0.05, 2.97]	0.04
HbA1c	6	378	Mean Difference (IV, Fixed, 95% CI)	-0.28 [-0.61, 0.04]	NS
HOMA-IR	5	373	Mean Difference (IV, Fixed, 95% CI)	-0.00 [-0.68, 0.68]	NS







Figure 1. Flow chart of studies included in the meta-analysis




A. The effects of green tea or its extract on FBG



B. The effects of green tea or its extract on FBI



C. The effects of green tea or its extract on HbA1c



D. The effects of green tea or its extract on HOMA-IR

Figure 2. Meta-analysis of the effects of green tea or its extract on blood glucose control and HOMA-IR